Next Article in Journal
Custom Made Replacement of the Mandibular Condyle in a Case of Fibrous Dysplasia with Cystic Degeneration; A Case Report
Next Article in Special Issue
Osteonecrosis of the Jaws (ONJ) after Bisphosphonate Treatment in Patients with Multiple Myeloma: Decreasing ONJ Incidence after Adoption of Preventive Measures
Previous Article in Journal
Environmental Factors Influencing Adoption of Canadian Guidelines on Smoking Cessation in Dental Healthcare Settings in Quebec: A Qualitative Study of Dentists’ Perspectives
Previous Article in Special Issue
Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases
Article Menu

Export Article

Open AccessReview
Dent. J. 2016, 4(4), 41; doi:10.3390/dj4040041

Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ)

1
Center for Refractory Jawbone Diseases, Department of Oral & Maxillofacial Surgery, Kyung Hee University Dental Hospital, Seoul 02447, Korea
2
Department of Nuclear Medicine, Kyung Hee University Hospital, Seoul 02447, Korea
*
Author to whom correspondence should be addressed.
Academic Editor: Christian Walter
Received: 20 September 2016 / Revised: 18 October 2016 / Accepted: 18 October 2016 / Published: 9 November 2016
(This article belongs to the Special Issue New Cancer and Osteoporosis Therapies and Osteocrosis of the Jaws)
View Full-Text   |   Download PDF [186 KB, uploaded 9 November 2016]

Abstract

While the optimal treatment concept of medication-related osteonecrosis of the jaws (MRONJ) is still in debate, several adjunct therapies have been introduced. Among these adjunctive measures, recombinant human parathyroid hormone (rhPTH, teriparatide) seems to be the most promising treatment modality. Several studies have presented the beneficial effect of short-term teriparatide; they have shown an improved level of bone markers and radiographic evidence of bone healing. Although clinical validation by a controlled trial with prospective design would be essential, short-term teripratide therapy would be a good treatment option for MRONJ patients with impaired bone remodeling. View Full-Text
Keywords: MRONJ; bisphosphonate; ONJ; teriparatide; parathyroid hormone MRONJ; bisphosphonate; ONJ; teriparatide; parathyroid hormone
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Kwon, Y.-D.; Kim, D.-Y. Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ). Dent. J. 2016, 4, 41.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Dent. J. EISSN 2304-6767 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top